|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300068264 |
|
最近更新日期: Date of Last Refreshed on: |
2023-02-13 14:20:29 |
|
注册时间: Date of Registration: |
2023-02-13 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
新型冠状病毒感染对术后并发症的影响:一项多中心队列研究 |
|
Public title: |
The impact of SARS-COV-2 infection on postoperative complications in surgical patients: a multicenter cohort study |
|
注册题目简写: |
新型冠状病毒感染对术后并发症的影响:一项多中心队列研究 |
|
English Acronym: |
The impact of SARS-COV-2 infection on postoperative complications in surgical patients: a multicenter cohort study |
|
研究课题的正式科学名称: |
新型冠状病毒感染对术后并发症的影响:一项多中心队列研究 |
|
Scientific title: |
The impact of SARS-COV-2 infection on postoperative complications in surgical patients: a multicenter cohort study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
孙小芬 |
研究负责人: |
谢言虎 |
|
Applicant: |
Xiaofen Sun |
Study leader: |
Yanhu Xie |
|
申请注册联系人电话: Applicant telephone: |
15956929256 |
研究负责人电话: Study leader's telephone: |
0551-62283499 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
sunxiaofen001@163.com |
研究负责人电子邮件: Study leader's E-mail: |
xyh200701@sina.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
安徽省合肥市政务区天鹅湖路1号 |
研究负责人通讯地址: |
安徽省合肥市政务区天鹅湖路1号 |
|
Applicant address: |
No.1 Swan Lake Road, Hefei, Anhui, ChinaV |
Study leader's address: |
No.1 Swan Lake Road, Hefei, Anhui, China |
|
申请注册联系人邮政编码: Applicant postcode: |
230000 |
研究负责人邮政编码: Study leader's postcode: |
230000 |
|
申请人所在单位: |
中国科学技术大学附属第一医院(安徽省立医院) |
||
|
Applicant's institution: |
The First Affiliated Hospital of University of Science and Technology of China |
||
|
研究负责人所在单位: |
中国科学技术大学附属第一医院(安徽省立医院) |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of University of Science and Technology of China |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023KY伦审第010号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国科学技术大学附属第一医院医学研究伦理委员会 |
||
|
Name of the ethic committee: |
Medical Research Ethics Committee of the First Affiliated Hospital of University of Science and Technology of China |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-02-10 00:00:00 |
||
|
伦理委员会联系人: |
沈佐君 |
||
|
Contact Name of the ethic committee: |
Zuojun Shen |
||
|
伦理委员会联系地址: |
安徽省合肥市庐江路17号安徽省立医院行政楼六楼 |
||
|
Contact Address of the ethic committee: |
Anhui Provincial Hospital, No. 17 Lujiang Road, Hefei, Anhui Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
0551-62282931 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中国科学技术大学附属第一医院(安徽省立医院) |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of University of Science and Technology of China |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
安徽省合肥市政务区天鹅湖路1号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.1 Swan Lake Road, Hefei, Anhui, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
研究者自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
self-raised funding |
||||||||||||||||||||||
|
Target disease: |
SARS-COV-2 infection |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
观察新型冠状病毒感染对术后并发症的影响 |
||||||||||||||||||||||
|
Objectives of Study: |
To observe the impact SARS-COV-2 infection on postoperative complications in surgical patients |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
新型冠状病毒感染的确诊病例和临床诊断病例;年龄≥18岁;ASA I~III级; |
||||||||||||||||||||||
|
Inclusion criteria |
Confirmed and clinically diagnosed cases of novel coronavirus infection; Age ≥ 18 years old; ASA Class I~III; |
||||||||||||||||||||||
|
排除标准: |
预计生存≤24H;术前合并严重心肺功能损害,肺功能重度损害,慢阻肺急性发作,活动性肺炎,基础血氧≤90%,心脏瓣膜重度狭窄(关闭不全),不稳定性心绞痛的患者;严重肝肾功能损害,Child分级C级,需维持性透析患者;心脏外科、胸外科及脑外科三类术后肺部并发症多的手术;患者拒绝及无法获取相关病史的患者 |
||||||||||||||||||||||
|
Exclusion criteria: |
Predictable survival time ≤ 24H; Severe cardiopulmonary dysfunction, basic SPO2 ≤ 90%; Severe impairment of liver and kidney function, and patients who need maintenance dialysis; Cardiac surgical, thoracic surgical and neurosurgical patients at high risk for pulmonary complications;Patients who refuse to offer relevant medical history |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-02-12 00:00:00至 To 2024-02-12 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-02-12 00:00:00 至 To 2024-02-12 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不适用 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Not applicable |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
不设盲 |
|
Blinding: |
Not applicable |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
若研究对象或相关机构有正当理由可通过联系项目负责人获得 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
please contact with the study leader with Email or Wechat |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据提取与收集:研究数据源为医院信息系统中原始的病案记录、检验、检查报告。医院信息系统外的其它信息由临床一线医生和医疗团队负责收集,记录于REDcap数据库。 数据管理:依据病历、检验结果、影像学资料由临床工作背景者录入数据库,临床流行流行病学研究中心负责汇总进行数据管理和数据审核。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data extraction and collection: The research data source is the original medical record records, inspection and inspection reports in the hospital information system. Additional information outside the hospital information system is collected by the clinical front-line physician and medical team and recorded in the REDcap database. Data management: According to medical records, test results and imaging data, patients with clinical work background will enter into the database, and clinical Epidemiology Research Center will be responsible for data management and data review. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |